Please login to the form below

Not currently logged in

autoimmune disease

This page shows the latest autoimmune disease news and features for those working in and with pharma, biotech and healthcare.

Astellas, Catalyst approvals set up record year for FDA approvals

Astellas, Catalyst approvals set up record year for FDA approvals

The approvals of Astellas’ FLT3 inhibitor Xospata (gilteritinib) for acute myeloid leukaemia and Catalyst Pharmaceuticals’ Firdapse (amifampridine) for rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS), already put the number for

Latest news

More from news
Approximately 3 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to

  • Reaching new heights Reaching new heights

    Transformative medicine use. The overwhelming inertia in medicine use - where 97% of medicines used have been available for more than ten years - masks the contribution from transformative disease treatments, orphan drugs ... Disease treatments in 2020

  • Pharma deals during May 2014 Pharma deals during May 2014

    Lumena develops oral products for treating liver disease and has two oral inhibitors of the apical sodium-dependent bile acid transporter (ASBT) in phase II to improve liver function. ... MGD010 a B-cell targeted monoclonal antibody for treatment of

  • The distressing impact of rare diseases The distressing impact of rare diseases

    The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Akari Therapeutics strengthens board Akari Therapeutics strengthens board

    His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and ... As Akari continues its mission to develop

  • David Horn Solomon takes the helm of Akari Therapeutics David Horn Solomon takes the helm of Akari Therapeutics

    biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.

  • Caldan Therapeutics appoints CEO Caldan Therapeutics appoints CEO

    Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014. ... He co-founded autoimmune disease-focused Orca

  • Santhera CEO Klaus Schollmeier joins SuppreMol Santhera CEO Klaus Schollmeier joins SuppreMol

    In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires. ... He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).


    Meet Irene. Like millions of others worldwide (and an estimated 115, 000 in the UK), Irene suffers from Crohn’s disease, an autoimmune disorder that causes inflammation in the gut and ... She believes that they follow a “by-the-book” mentality, not

  • What next for the treatment of Psoriasis in Europe?

    Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. ... A chronic autoimmune disease, psoriasis has an estimated

  • Patient Persepective: Autoimmune Disease

    Autoimmune diseases affect 1–5% of the World’s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including Crohn’s disease, a form of inflammatory bowel

  • Latest wave of Therapy Watch IBD to run this month

    A panel of 200 gastroenterologists will report in 10 IBD patient record forms each quarter (5 Crohn’s disease and 5 ulcerative colitis), to monitor the evolving IBD treatment landscape.

More from PMHub
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...